ValuEngine upgraded shares of NxStage Medical (NASDAQ:NXTM) from a hold rating to a buy rating in a research report released on Friday morning.
Several other analysts have also recently commented on NXTM. BidaskClub raised NxStage Medical from a hold rating to a buy rating in a research report on Tuesday, June 26th. Zacks Investment Research raised NxStage Medical from a sell rating to a hold rating in a research report on Wednesday, July 18th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $30.00.
Shares of NxStage Medical stock traded up $0.42 during midday trading on Friday, hitting $27.99. The company’s stock had a trading volume of 416,562 shares, compared to its average volume of 486,566. The stock has a market cap of $1.83 billion, a PE ratio of -127.23 and a beta of -0.06. NxStage Medical has a 1-year low of $22.70 and a 1-year high of $28.75.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of NxStage Medical by 10.5% during the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock worth $147,581,000 after acquiring an additional 501,922 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of NxStage Medical during the second quarter worth $11,424,000. LMR Partners LLP purchased a new stake in shares of NxStage Medical during the second quarter worth $7,438,000. Water Island Capital LLC raised its holdings in shares of NxStage Medical by 12.6% during the second quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock worth $37,230,000 after acquiring an additional 149,713 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of NxStage Medical during the second quarter worth $3,962,000. 83.12% of the stock is owned by institutional investors and hedge funds.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Further Reading: Cash Flow Analysis in Stock Selection
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.